Journey Colab’s first compound in development is Mescaline HCI (JOUR-5700), a novel potential treatment for AUD
Journey Colab has completed its non-clinical and CMC programs to support its Phase 1 First-In-Human study of JOUR-5700.
The Science of Mescaline
JOUR-5700 (Mescaline HCl) is a classic serotonergic psychedelic that binds and activates the serotonin 2a (5-HT2a receptor) in key cortical and subcortical structures associated with addiction, emotion, mood, personality, cognition, motivation, and perception. Early research suggests this activity may result in neuroplasticity and neurogenesis.
Other classic psychedelics operating on the 5-HT2a receptor have shown some early efficacy in human studies as possible treatments for alcohol use disorder and tobacco addiction, and numerous debilitating neuropsychiatric conditions, with effects that may persist for weeks or months following a single dose.
Mescaline HCl has a promising safety profile and longer-lasting therapeutic effects.
Mescaline HCl may provide a less intense and more insightful experience than other psychedelics, allowing for patients to experience a greater degree of mental clarity and connectedness to others that could promote psychotherapy.